# Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

> **NCT03969849** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 96 (actual)

## Conditions studied

- Healthy Volunteers
- Birch Pollen Allergy

## Interventions

- **DRUG:** REGN5713-5714-5715
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT03969849
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2020-03-27
- **Final completion:** 2020-03-27
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03969849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03969849, "Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03969849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*